JF’s Core Biotech Buys #10: Incyte Disappoints, Optimism Returns To Gene Therapy And A New Position – Seeking Alpha
|
JF's Core Biotech Buys #10: Incyte Disappoints, Optimism Returns To Gene Therapy And A New Position
Seeking Alpha The rollercoaster ride in the gene therapy space (pessimism due to clinical hold/safety fears followed by optimism over Novartis acquiring AveXis) has been an interesting case study to watch. We took advantage of undeserved pessimism by filling out … |
